@article{oai:repo.qst.go.jp:00085267,
 author = {Kuan, Hu and Ma, Xiaohui and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Honoka, Obata and Zhang, Lulu and Kotaro, Nagatsu and Hisashi, Suzuki and Shi, Rui and Wang, Weizhi and Zhang, Ming-Rong and Kuan, Hu and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Honoka, Obata and Kotaro, Nagatsu and Hisashi, Suzuki and Zhang, Ming-Rong},
 issue = {1},
 journal = {ACS Omega},
 month = {Dec},
 note = {CD133 has been recognized as a prominent biomarker for cancer stem cells (CSCs), which promote tumor relapse and metastasis. Herein, we developed a clinically relevant, stable, peptide-based positron emission tomography (PET) tracer, [64Cu]CM-2, for mapping CD133 protein in several kinds of cancers. Through the incorporation of a 6-aminohexanoic acid (Ahx) into the N-terminus of a CM peptide, we constructed a stable peptide tracer [64Cu]CM-2, which exhibited specific binding to CD133-positive CSCs in multiple preclinical tumor models. Both PET imaging and ex vivo biodistribution verified the superb performance of [64Cu]CM-2. Furthermore, the matched physical- and biological half-life of [64Cu]CM-2 makes it a state-of-art PET tracer for CD133. Therefore, [64Cu]CM-2 PET may not only enable the longitudinal tracking of CD133 dynamics in the cancer stem cell niche, but also provide a powerful and noninvasive imaging tool to track down CSCs in refractory cancers.},
 pages = {334--341},
 title = {Development of a stable peptide-based PET tracer for detecting CD133-expressing cancer cells},
 volume = {7},
 year = {2021}
}